Prairie Operating Co. logo

Prairie Operating Co. (7C5)

Market Open
5 Dec, 14:30
1. 54
+0.05
+3.36%
- Market Cap
- P/E Ratio
0.4% Div Yield
0 Volume
- Eps
1.49
Previous Close
Day Range
1.49 1.54
Year Range
1.35 7.45
Want to track 7C5 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

7C5 trading today higher at €1.54, an increase of 3.36% from yesterday's close, completing a monthly increase of 1.32% or €0.02. Over the past 12 months, 7C5 stock lost -79.33%.
7C5 is not paying dividends to its shareholders.
The last earnings report, released on Nov 14, 2025, missed the consensus estimates by -0.8%. On average, the company has fell short of earnings expectations by -0.76%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 11 different exchanges and in various currencies, with the primary listing on NYSE (USD).

7C5 Chart

Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript

Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript

Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seekingalpha | 2 days ago
Charles River Laboratories International, Inc. (CRL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Charles River Laboratories International, Inc. (CRL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Charles River Laboratories International, Inc. ( CRL ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Birgit Girshick - Corporate Executive VP & COO Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division All right. Good morning, everybody.

Seekingalpha | 2 weeks ago
Charles River (CRL) International Revenue Performance Explored

Charles River (CRL) International Revenue Performance Explored

Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Zacks | 2 weeks ago

Prairie Operating Co. (7C5) FAQ

What is the stock price today?

The current price is €1.54.

On which exchange is it traded?

Prairie Operating Co. is listed on NYSE.

What is its stock symbol?

The ticker symbol is 7C5.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.4%.

What is its market cap?

As of today, no market cap data is available.

Has Prairie Operating Co. ever had a stock split?

No, there has never been a stock split.

Prairie Operating Co. Profile

- Industry
- Sector
James C. Foster CEO
XFRA Exchange
US1598641074 ISIN
US Country
18,700 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Charles River Laboratories International, Inc. stands as a pivotal organization within the pharmaceutical industry, providing a comprehensive suite of services encompassing drug discovery, non-clinical development, and safety testing. With a global footprint that extends across the United States, Europe, Canada, the Asia Pacific, and other international markets, the company is recognized for its integrated solutions that support the entire drug development cycle. It operates through three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing), each tailored to meet the varied and complex needs of its clients. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories is dedicated to aiding its clients in the development of novel therapies and medicines through its vast expertise and comprehensive facilities.

Products and Services

Research Models and Services (RMS): This segment is integral to Charles River Laboratories' operations, producing and selling a wide variety of research rodents, including purpose-bred rats and mice. These are essential tools for researchers across the globe, enabling a myriad of scientific investigations and discoveries. Services offered within this segment also include:

  • Genetically Engineered Models and Services: Customization and production of genetically modified animals to meet specific research requirements.
  • Insourcing Solutions: Provision of skilled personnel and resources to manage and operate clients' laboratory animal facilities.
  • Research Animal Diagnostic Services: Comprehensive diagnostic services to ensure the health and genetic integrity of research models.

Discovery and Safety Assessment (DSA): A critical segment that supports early-stage drug discovery and safety assessment. The DSA segment delivers:

  • Early and in vivo Discovery Services: Identification and validation of novel targets, chemical compounds, and antibodies, alongside the delivery of preclinical drug and therapeutic candidates ready for safety assessment.
  • Safety Assessment Services: Extensive testing services including toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics to ensure candidate drugs are safe for clinical trials.

Manufacturing Solutions (Manufacturing): This segment provides critical support in the quality control and testing of pharmaceuticals and consumer products. It encompasses:

  • In vitro Methods for Quality Control: Testing services for both sterile and non-sterile pharmaceuticals and consumer products, including specialized testing of biologics outsourced by pharmaceutical and biotechnology companies.
  • Contract Vivarium Operation Services: Operational support for biopharmaceutical clients’ vivarium facilities, ensuring the maintenance of high-quality standards in animal care and research.

Contact Information

Address: 251 Ballardvale Street
Phone: 781 222 6000